Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design

Catenacci, DVT; Tesfaye, A; Tejani, M; Cheung, E; Eisenberg, P; Scott, AJ; Eng, C; Hnatyszyn, J; Marina, N; Powers, J; Wainberg, Z

Catenacci, DVT (reprint author), Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA.

FUTURE ONCOLOGY, 2019; 15 (18): 2073

Abstract

Bemarituzumab is an afucosylated monoclonal antibody against FGFR2b (a FGF receptor) with demonstrated monotherapy clinical activity in patients with ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索